Replies to post #391589 on Anavex Life Sciences Corp (AVXL)

[DFRAI]

Pretty much shows disease slightly better than baseline and much superior to Lecanemab results which are declining from baseline

[avxl_going_long]

"improvement" is the operative word here

[frrol]

It is, practically speaking. But over a 48 week period, which is a sufficiently long time, someone with AD is going to have a definite decline (eg, average 4.11 points for our placebo arm, with just .86 SE). Stability, or even slight improvement, is clearly clinically significant.